neoplasms . Cancer Discov 2016 ; 6 : 154 – 165 . 26566875 10.1158/2159-8290.CD-15-0913 3. Badalian-Very G , Vergilio JA , Degar BA , Recurrent BRAF mutations in Langerhans cell histiocytosis . Blood 2010 ; 116 : 1919 – 1923
Search Results
Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation
Boyu Hu, Jay L. Patel, Randa Tao, Richard B. Cannon, Marcus Monroe, and Gaurav Goyal
Role of Molecular Profiling in Soft Tissue Sarcoma
Timothy Lindsay and Sujana Movva
600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours . J Clin Pathol 2009 ; 62 : 613 – 616 . 33. Hostein I Faur N Primois C . BRAF mutation status in
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
David S. Ettinger, Dara L. Aisner, Douglas E. Wood, Wallace Akerley, Jessica Bauman, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, Michael Dobelbower, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Sandip P. Patel, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
% of patients with lung adenocarcinoma who are typically current or former smokers. 65 – 67 BRAF mutations typically do not overlap with EGFR mutations or ALK rearrangements. 65 , 68 The NCCN panel recommends testing for BRAF mutations based
Constitutional MLH1 Methylation Is a Major Contributor to Mismatch Repair–Deficient, MLH1-Methylated Colorectal Cancer in Patients Aged 55 Years and Younger
Megan P. Hitchins, Estela Dámaso, Rocio Alvarez, Lisa Zhou, Yajing Hu, Marcio A. Diniz, Marta Pineda, Gabriel Capella, Rachel Pearlman, and Heather Hampel
2010 ; 12 : 498 – 504 . 20489114 20. Nakagawa H , Nagasaka T , Cullings HM , Efficient molecular screening of Lynch syndrome by specific 3′ promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high
NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies
Alan P. Venook, Maria E. Arcila, Al B. Benson III, Donald A. Berry, David Ross Camidge, Robert W. Carlson, Toni K. Choueiri, Valerie Guild, Gregory P. Kalemkerian, Razelle Kurzrock, Christine M. Lovly, Amy E. McKee, Robert J. Morgan, Anthony J. Olszanski, Mary W. Redman, Vered Stearns, Joan McClure, and Marian L. Birkeland
learning throughout the trial lifecycle. As an example of the challenges, consider the situation in which a trial required validated testing for specific BRAF mutations across a variety of tumor types. Methods available to accomplish this included
Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma
Matthew Zibelman and Anthony J. Olszanski
. Molecular testing results became available and demonstrated a V600K BRAF mutation (c.1798_1799GT>AA). The patient was referred to ophthalmology and the decision was made to proceed with the third dose of ipilimumab. Two weeks later, the patient presented
Management of Patients With Advanced Melanoma
Presented by: Genevieve Boland
lymph nodes,” Dr. Boland said. Patients need to be tested for BRAF mutation status, staged appropriately, and surgically managed (wide excision, LND), with consideration given to enrolling appropriate patients in neoadjuvant trials. Adjuvant
NCCN Guidelines Insights: Rectal Cancer, Version 6.2020
Featured Updates to the NCCN Guidelines
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Alyse Johnson-Chilla, and Lisa A. Gurski
5% to 9% of CRCs are characterized by a specific mutation in the BRAF gene (V600E). 32 , 33 BRAF mutations are, for all practical purposes, limited to tumors that do not have KRAS exon 2 mutations. 32 – 34 The NCCN panel currently recommends
Managing the Financial Impact of Cancer Treatment: The Role of Clinical Practice Guidelines
Scott Ramsey and Veena Shankaran
overall survival according to tumor KRAS and BRAF mutation status . J Clin Oncol 2011 ; 29 : 2011 – 2019 . 10 Douillard JY Siena S Cassidy J . Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and
Ten Years of Progress in Melanoma
John A. Thompson
trial, 675 patients with metastatic melanoma and BRAF mutation (as detected with the COBAS 4800 V600E mutation test) were randomized to vemurafenib (960 mg orally, twice daily) versus dacarbazine (1000 mg/kg every 3 weeks). 12 The hazard ratio for
